Recombinant activated protein C: decisions for administration.
Dellinger
R Phillip
RP
Section of Critical Care Medicine, Cooper University Hospital, Camden, NJ, USA.
D018806:APACHE; D001291:Attitude of Health Personnel; D002986:Clinical Trials as Topic; D003657:Decision Making; D017277:Drug Approval; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D018805:Sepsis / Q000145:classification / Q000188:drug therapy* / Q000401:mortality; D014481:United States; D014486:United States Food and Drug Administration
D005343:Fibrinolytic Agents; D011486:Protein C